Search

Displaying results 1151 - 1160 of 1745 in total
  1. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic n...

  2. Drug

    Gold

    go.drugbank.com/drugs/DB14154
    Investigational

    A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration.

  3. Drug

    Hard fat

    go.drugbank.com/drugs/DB11578
    Approved

    Mixtures: Anu-Med
  4. Drug

    Albendazole

    go.drugbank.com/drugs/DB00518
    ApprovedInvestigationalVet approved

    A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)

    Synonyms: O-methyl N-(5-(propylthio)-2-benzimidazolyl)carbamateMixtures: LOXCELL NF
  5. Drug

    N-alkyl ethylbenzyl dimethyl ammonium (C12-C14)

    go.drugbank.com/drugs/DB11202
    Approved

    N-alkyl ethylbenzyl dimethyl ammonium (c12-c14) is a quaternary ammonium compound with surfactant properties. … gram-positive and gram-negative antibacterial activities and relatively little chance for systemic absorption and exposure, although the formal mechanism of action of quaternary ammonium compounds like n-alkyl

    Salts: N-alkyl ethylbenzyl dimethyl ammonium chloride (C12-C14)Mixtures: Mevon No. 72 Liq
  6. Drug

    Belumosudil

    go.drugbank.com/drugs/DB16703
    ApprovedInvestigational

    [A236634] It is an inhibitor of rho-associated coiled-coil-containing protein kinases (ROCK), with significantly more selectivity for ROCK2 as compared to ROCK1 (IC<sub>50</sub> 100 nM vs. 3 μM, respectively

  7. Drug

    Ensartinib

    go.drugbank.com/drugs/DB14860
    ApprovedInvestigational

    [L53263] Although there was no statistically significant difference in overall survival when compared to [crizotinib], ensartinib demonstrated a statistically significant progression-free survival improvement

  8. Drug

    Cefiderocol

    go.drugbank.com/drugs/DB14879
    ApprovedInvestigational

    [L10893] It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.

  9. Drug

    Acalabrutinib

    go.drugbank.com/drugs/DB11703
    ApprovedInvestigational

    To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administer...

  10. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regula...